加州大学洛杉矶分校(UCLA)研究人员发布的一项初步临床试验结果表明,补充天然分子草酰乙酸可能有助于缓解乳腺癌幸存者的“脑雾”症状及疲劳 1。该研究由UCLA Health Jonsson Comprehensive Cancer Center的研究人员主导,结果发表于《JCO Oncology Advances》期刊 1。参与试验的18名女性受试者均为确诊早期乳腺癌1至5年的患者,平均年龄约为50岁 1。在为期八周的干预期间,参与者每日两次服用500毫克草酰乙酸 1。数据显示,主要认知障碍感知评分的平均值从治疗前的29.1分显著提升至治疗后的55.5分,后者处于正常范围内 1。尽管这一变化令人鼓舞,但研究人员强调样本量较小且缺乏安慰剂对照,因此结论需通过更大规模的随机对照试验进一步验证 1。
安全性方面,试验中未出现严重不良反应,最常见的副作用为消化系统问题,包括消化不良和腹胀 1。共有两名女性因胃肠道症状而停止服药 1。这项研究部分由乳腺癌研究基金会和美国国家癌症研究所资助 1。为了更严谨地评估疗效,研究团队计划于2026年底启动一项包含安慰剂对照的二期随机临床试验 1。
Researchers at the UCLA Health Jonsson Comprehensive Cancer Center have published findings from a preliminary clinical trial indicating that oxaloacetate, a naturally occurring molecule, may help alleviate cognitive impairment and fatigue commonly referred to as "brain fog" among breast cancer survivors. 1 The study results were featured in the journal JCO Oncology Advances. 1 While the outcomes are encouraging, the investigators cautioned that the small sample size and lack of a placebo control group limit the conclusions, necessitating verification through larger randomized controlled trials. 1
The trial enrolled 18 women with an average age of approximately 50 who had been diagnosed with early-stage breast cancer one to five years prior. 1 Participants took 500 mg of oxaloacetate twice daily for eight weeks. 1 During this period, the mean score on the primary measure of perceived cognitive dysfunction rose significantly from 29.1 before treatment to 55.5 afterward, reaching the normal range. 1 No severe adverse events were reported; however, common side effects included gastrointestinal issues such as indigestion and bloating, which led two participants to discontinue the medication. 1 The research received partial funding from the Breast Cancer Research Foundation and the U.S. National Cancer Institute. 1 A follow-up phase II randomized clinical trial incorporating a placebo control is scheduled to begin by late 2026. 1
评论
还没有评论,欢迎留下第一条。